Kurs & Likviditet
Kalender
2024-11-07 | Kvartalsrapport 2024-Q3 |
2024-08-15 | Kvartalsrapport 2024-Q2 |
2024-05-16 | Kvartalsrapport 2024-Q1 |
2024-03-21 | Ordinarie utdelning ZEAL 0.00 DKK |
2024-03-20 | Årsstämma 2024 |
2024-02-27 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-03-30 | Ordinarie utdelning ZEAL 0.00 DKK |
2023-03-29 | Årsstämma 2023 |
2023-03-02 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Kvartalsrapport 2022-Q2 |
2022-05-12 | Kvartalsrapport 2022-Q1 |
2022-05-09 | Ordinarie utdelning ZEAL 0.00 DKK |
2022-04-06 | Årsstämma 2022 |
2022-03-10 | Bokslutskommuniké 2021 |
2021-11-11 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Kvartalsrapport 2021-Q2 |
2021-05-12 | Kvartalsrapport 2021-Q1 |
2021-04-16 | Ordinarie utdelning ZEAL 0.00 DKK |
2021-04-15 | Årsstämma 2021 |
2021-03-11 | Bokslutskommuniké 2020 |
2020-11-12 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Kvartalsrapport 2020-Q2 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-04-03 | Ordinarie utdelning ZEAL 0.00 DKK |
2020-04-02 | Årsstämma 2020 |
2020-03-12 | Bokslutskommuniké 2019 |
2019-11-14 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-04-05 | Ordinarie utdelning ZEAL 0.00 DKK |
2019-04-04 | Årsstämma 2019 |
2019-03-07 | Bokslutskommuniké 2018 |
2018-11-15 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Kvartalsrapport 2018-Q1 |
2018-04-20 | Ordinarie utdelning ZEAL 0.00 DKK |
2018-04-19 | Årsstämma 2018 |
2018-03-07 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Kvartalsrapport 2017-Q1 |
2017-04-06 | Ordinarie utdelning ZEAL 0.00 DKK |
2017-04-05 | Årsstämma 2017 |
2017-03-15 | Bokslutskommuniké 2016 |
2016-11-09 | Kvartalsrapport 2016-Q3 |
2016-08-25 | Kvartalsrapport 2016-Q2 |
2016-05-18 | Kvartalsrapport 2016-Q1 |
2016-04-20 | Ordinarie utdelning ZEAL 0.00 DKK |
2016-04-19 | Årsstämma 2016 |
2016-03-16 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-28 | Kvartalsrapport 2015-Q2 |
2015-05-22 | Kvartalsrapport 2015-Q1 |
2015-04-22 | Ordinarie utdelning ZEAL 0.00 DKK |
2015-04-21 | Årsstämma 2015 |
2015-03-12 | Bokslutskommuniké 2014 |
2014-11-07 | Kvartalsrapport 2014-Q3 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Kapitalmarknadsdag 2014 |
2014-04-29 | Kvartalsrapport 2014-Q1 |
2014-04-29 | Årsstämma 2014 |
2014-03-21 | Ordinarie utdelning ZEAL 0.00 DKK |
2014-03-20 | Bokslutskommuniké 2013 |
2013-11-15 | Kvartalsrapport 2013-Q3 |
2013-08-29 | Kvartalsrapport 2013-Q2 |
2013-05-15 | Kvartalsrapport 2013-Q1 |
2013-04-30 | Årsstämma 2013 |
2013-04-30 | Ordinarie utdelning ZEAL 0.00 DKK |
2013-03-14 | Bokslutskommuniké 2012 |
2012-11-29 | Kapitalmarknadsdag 2012 |
2012-04-26 | Ordinarie utdelning ZEAL 0.00 DKK |
2012-04-25 | Årsstämma 2012 |
2011-11-17 | Kvartalsrapport 2011-Q3 |
2011-10-25 | Kapitalmarknadsdag 2011 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-05-12 | Kvartalsrapport 2011-Q1 |
2011-04-29 | Ordinarie utdelning ZEAL 0.00 DKK |
2011-04-28 | Årsstämma 2011 |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Bioteknik |
Company announcement – No. 8 / 2021
Copenhagen, DK February 23, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in March:
Credit Suisse 2021 London Global Healthcare Conference
Date: Tuesday, March 2, 2021
Jefferies Pan-European Mid-Cap Virtual Conference
Date: Tuesday, March 30, 2021
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
For further information, please contact:
Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com